Trial Profile

A retrospective study of efficacy and safety of pembrolizumab plus lenvatinib plus hepatic arterial infusion chemotherapy (HAIC) versus pembrolizumab plus lenvatinib in patients with treatment-naive unresectable hepatocellular carcinoma

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 15 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
Indications Liver cancer
Focus Therapeutic Use

15 Feb 2022 New trial record
19 Oct 2021 Primary endpoint (progression-free survival (PFS)) has been met, according to Results published in the BMC Cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com